EPIX News and Press, ESSA Pharma Inc.

ESSA Pharma to Present at the JonesHealthcare Seaside Summit Canada NewsWire SOUTH SAN FRANCISCO, Calif. and VANCOUVER, BC , July 8, 2024 /CNW/ - ESSA Pharma Inc. ("ESSA," or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on de...

ESSA Pharma to Present at the Jefferies Global Healthcare Conference Canada NewsWire SOUTH SAN FRANCISCO, Calif. and VANCOUVER, BC , May 30, 2024 /CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focus...

2024-05-29 17:44:01 ET Summary ESSA Pharma Inc. is developing Masofaniten, a drug that disrupts the androgen receptor to stop prostate cancer growth, with promising results in phase 1 trials. Masofaniten has the potential to overcome resistance to other standard-of-care treatments...

2024-05-14 13:54:55 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips ESSA Pharma (NASDAQ: EPIX ) just reported results for the second quarter of 2024. ESSA Pharma reported earnings per share of -20 cents. This was below the analyst estimate...

2024-05-14 07:19:06 ET More on ESSA Pharma Seeking Alpha’s Quant Rating on ESSA Pharma Historical earnings data for ESSA Pharma Financial information for ESSA Pharma Read the full article on Seeking Alpha For further details see: ESSA Pharm...

ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2024 Canada NewsWire Combination of masofaniten plus enzalutamide continues to be well tolerated with deep and durable reductions in PSA in Phase 1 dose escalation in ...

ESSA Pharma to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference ESSA Pharma to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference Canada NewsWire SOUTH SAN FRANCISCO , Calif. and VANCOUVER, BC , April 9, 2...

2024-03-27 01:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-02-14 02:18:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal First Quarter Ended December 31, 2023 Canada NewsWire Combination of masofaniten plus enzalutamide continues to be well tolerated with deep and durable reductions in PSA in Phase 1 dose escalation i...